STOCK TITAN

Lakewood-Amedex risks Nasdaq suspension November 19

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Lakewood-Amedex Biotherapeutics Inc. (LABT) reported no revenue and a nine-month net loss of $6,170,030, versus $3,102,719 a year earlier; net cash used in operations was $3,714,859, versus $1,522,688. In September 2026, it dosed the first patient in its Phase 2a trial of Nu-3 for mildly infected diabetic foot ulcers.

At September 30, 2026, cash and cash equivalents were $2,823,636 and certificates of deposit were $500,000. Management expects existing resources to fund operations through January 2027, but says additional capital is required and substantial doubt remains about the company’s ability to continue as a going concern. After quarter-end, the company paid $1,270,970 to redeem 127,097 remaining Series C preferred shares, extinguishing their conversion rights.

Nasdaq notified LABT that its closing bid price was below the $1.00 minimum for 30 consecutive business days from September 29 through November 9, 2026, and Staff determined to delist its securities. The company intends to request a hearing; absent a request by November 17, 2026, trading could be suspended November 19, 2026. A timely hearing request would stay suspension pending the Panel’s decision.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

4 major · 4 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • None.

Negative

  • Major pointGoing-concern warning: substantial doubt remains within one year after issuance.
  • Major pointNine-month net loss: $6,170,030 versus $3,102,719.
  • Major pointOperating cash use: $3,714,859 versus $1,522,688 for nine months.
  • Major point. Forward-looking: it has not happened yet and may not happen.Nasdaq: potential suspension November 19, 2026 without a hearing request.

Filing Explained

The October charter amendment raised authorized common shares from 12.5 million to 100 million, adding issuance capacity without itself issuing shares.

Form 10-Q reports interim financial statements and updates on risks and liquidity. From October 15 through November 2, the Series C holder converted 176,138 preferred shares into 5,100,350 common shares, and common shares outstanding rose from 3,659,688 at September 30 to 8,950,088; on November 4, the company completed the redemption of the remaining 127,097 preferred shares, ending their conversion rights. The conversions increased the share count and reduced existing holders’ percentage ownership absent offsetting changes; the redemption ended further conversion-based issuance but did not reverse shares already issued.

Separately, shareholders approved an increase in authorized common shares from 12.5 million to 100 million, which the company filed in October and which became effective upon filing; this expands the number of shares the company is authorized to issue but does not itself issue shares.

For the Nu-3 Phase 2a trial, $505,764 of estimated costs under the PERI clinical research agreement remained to be incurred at September 30, subject to changes in scope, pass-through costs and other project activities. The Pace manufacturing agreement provides for fixed fees of $197,125, plus pass-through costs then estimated at 40% to 45% of those fees.

Net loss $6,170,030 Nine months ended September 30, 2026; $3,102,719 for the same period in 2025.
Net cash used in operating activities $3,714,859 Nine months ended September 30, 2026; $1,522,688 for the same period in 2025.
Cash and cash equivalents $2,823,636 As of September 30, 2026.
Certificates of deposit $500,000 Carrying value as of September 30, 2026.
Expected operating runway Through January 2027 Management’s estimate based on its current operating plan and available resources.
Series C financing net proceeds Approximately $6.8 million Financing completed during the nine months ended September 30, 2026.
Series C preferred stock redemption $1,270,970 Paid November 2, 2026, to repurchase and cancel 127,097 remaining shares.
Minimum continued-listing bid price $1.00 per share Nasdaq said the closing bid price was below this minimum for 30 consecutive business days from September 29 through November 9, 2026.
going concern financial
"substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
Phase 2a clinical trial medical
"first patient was dosed in its Phase 2a clinical trial"
A phase 2a clinical trial is an early-stage human study that tests a medical treatment in a small group of patients to learn whether it appears to work, to refine the right dose, and to monitor short-term safety. Investors watch these trials like prototype test drives: positive results reduce uncertainty about a drug’s chances, help estimate remaining development time and cost, and often trigger valuation changes or partnership interest in a drug program.
Bid Price Rule regulatory
"minimum required for continued listing under the Bid Price Rule"
beneficial ownership limitation financial
"Conversion is subject to a 4.99% beneficial ownership limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
anti-dilutive financial
"all potentially dilutive securities were anti-dilutive"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.
variable-price conversion feature technical
"potential for further dilution from the variable-price conversion feature"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why could LABT be suspended from Nasdaq?

Nasdaq Staff determined to delist LABT after its closing bid price stayed below the $1.00 minimum for 30 consecutive business days from September 29 through November 9, 2026. The company intends to request a hearing by November 17, 2026; a timely request would stay suspension pending the Panel’s decision.

How much did LABT pay to redeem its remaining Series C preferred stock?

On November 2, 2026, LABT paid $1,270,970 to repurchase and cancel 127,097 remaining Series C preferred shares. The transaction retired the shares and extinguished their associated conversion rights.

What is Nu-3’s Phase 2a trial evaluating?

The trial is evaluating Nu-3 dosing and administration for the treatment of mildly infected diabetic foot ulcers. LABT reported that the first patient was dosed in September 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
http://fasb.org/srt/2026#ChiefExecutiveOfficerMember P10Y P2Y P10Y 1 0002079272 false Q3 --12-31 0002079272 2026-07-01 2026-09-30 0002079272 2026-06-22 2026-06-22 0002079272 us-gaap:SubsequentEventMember 2026-11-10 0002079272 us-gaap:SubsequentEventMember 2026-11-10 2026-11-10 0002079272 us-gaap:SubsequentEventMember 2026-11-02 2026-11-02 0002079272 labt:SeriesCConvertiblePreferredStockMember 2026-01-01 2026-09-30 0002079272 2026-01-01 2026-09-30 0002079272 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0002079272 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-10-15 2026-11-02 0002079272 us-gaap:SubsequentEventMember labt:SeriesCConvertiblePreferredStockMember 2026-10-15 2026-11-02 0002079272 us-gaap:CommonStockMember us-gaap:SubsequentEventMember labt:SeriesCConvertiblePreferredStockMember 2026-10-01 2026-10-14 0002079272 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-10-01 2026-10-14 0002079272 us-gaap:SubsequentEventMember labt:SeriesCConvertiblePreferredStockMember 2026-10-01 2026-10-14 0002079272 2025-01-01 2025-09-30 0002079272 labt:FacilityCostsMember 2025-01-01 2025-09-30 0002079272 labt:FacilityCostsMember 2026-01-01 2026-09-30 0002079272 labt:PersonnelMember 2025-01-01 2025-09-30 0002079272 labt:PersonnelMember 2026-01-01 2026-09-30 0002079272 labt:CorporateExpensesMember 2025-01-01 2025-09-30 0002079272 labt:CorporateExpensesMember 2026-01-01 2026-09-30 0002079272 labt:ProfessionalServicesMember 2025-01-01 2025-09-30 0002079272 labt:ProfessionalServicesMember 2026-01-01 2026-09-30 0002079272 labt:OtherMember 2025-01-01 2025-09-30 0002079272 labt:OtherMember 2026-01-01 2026-09-30 0002079272 labt:ClinicalAndPreclinicalActivitiesMember 2025-01-01 2025-09-30 0002079272 labt:ClinicalAndPreclinicalActivitiesMember 2026-01-01 2026-09-30 0002079272 2025-07-01 2025-09-30 0002079272 labt:FacilityCostsMember 2025-07-01 2025-09-30 0002079272 labt:FacilityCostsMember 2026-07-01 2026-09-30 0002079272 labt:ProfessionalServicesMember 2025-07-01 2025-09-30 0002079272 labt:ProfessionalServicesMember 2026-07-01 2026-09-30 0002079272 labt:PersonnelMember 2025-07-01 2025-09-30 0002079272 labt:PersonnelMember 2026-07-01 2026-09-30 0002079272 labt:CorporateExpensesMember 2025-07-01 2025-09-30 0002079272 labt:CorporateExpensesMember 2026-07-01 2026-09-30 0002079272 labt:OtherMember 2025-07-01 2025-09-30 0002079272 labt:OtherMember 2026-07-01 2026-09-30 0002079272 labt:ClinicalAndPreclinicalActivitiesMember 2025-07-01 2025-09-30 0002079272 labt:ClinicalAndPreclinicalActivitiesMember 2026-07-01 2026-09-30 0002079272 us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0002079272 us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0002079272 us-gaap:ResearchAndDevelopmentExpense 2025-01-01 2025-09-30 0002079272 us-gaap:ResearchAndDevelopmentExpense 2026-01-01 2026-09-30 0002079272 us-gaap:GeneralAndAdministrativeExpense 2025-07-01 2025-09-30 0002079272 us-gaap:GeneralAndAdministrativeExpense 2026-07-01 2026-09-30 0002079272 us-gaap:ResearchAndDevelopmentExpense 2025-07-01 2025-09-30 0002079272 us-gaap:ResearchAndDevelopmentExpense 2026-07-01 2026-09-30 0002079272 us-gaap:WarrantMember 2026-09-30 0002079272 us-gaap:WarrantMember 2025-01-01 2025-09-30 0002079272 us-gaap:WarrantMember 2025-07-01 2025-09-30 0002079272 us-gaap:WarrantMember 2026-01-01 2026-09-30 0002079272 2026-04-24 2026-04-24 0002079272 us-gaap:WarrantMember 2026-04-24 0002079272 us-gaap:WarrantMember srt:DirectorMember 2026-04-24 2026-04-24 0002079272 labt:StockOptionsOutstandingMember 2026-09-30 0002079272 2026-09-30 0002079272 us-gaap:BlackScholesMertonModelMember 2026-01-01 2026-09-30 0002079272 labt:TwoThousandTwentyEquityIncentivePlanMember 2026-09-30 0002079272 us-gaap:SeriesCPreferredStockMember 2026-01-01 2026-09-30 0002079272 us-gaap:SeriesCPreferredStockMember 2026-09-30 0002079272 us-gaap:SeriesCPreferredStockMember 2026-04-21 0002079272 labt:SeriesAPreferredConvertedSharesOfCommonStockMember 2026-01-01 2026-09-30 0002079272 labt:TwoThousandTwentyEquityIncentivePlanMember 2026-09-22 2026-09-22 0002079272 2026-09-22 2026-09-22 0002079272 labt:TwoThousandTwentyEquityIncentivePlanMember labt:SeriesCConvertiblePreferredStockMember 2026-09-22 0002079272 srt:MaximumMember labt:TwoThousandTwentyEquityIncentivePlanMember 2026-09-22 2026-09-22 0002079272 srt:MinimumMember labt:TwoThousandTwentyEquityIncentivePlanMember 2026-09-22 2026-09-22 0002079272 labt:SeriesCConvertiblePreferredStockMember 2026-09-30 0002079272 labt:IssuanceUponConversionOfSeriesCConvertiblePreferredStockMember 2026-09-30 0002079272 labt:WarrantsOutstandingMember 2026-09-30 0002079272 labt:StockOptionsOutstandingOutsideThe2020EquityIncentivePlanMember 2026-09-30 0002079272 labt:StockOptionsOutstandingUnderThe2020EquityIncentivePlanMember 2026-09-30 0002079272 labt:SharesReservedForFutureIssuanceUnderTheTwoThousandTwentyEquityIncentivePlanMember 2026-09-30 0002079272 us-gaap:CommonStockMember srt:MaximumMember 2026-09-22 0002079272 us-gaap:CommonStockMember srt:MinimumMember 2026-09-22 0002079272 us-gaap:CommonStockMember labt:LegalServicesProvidedMember 2026-01-01 2026-09-30 0002079272 us-gaap:CommonStockMember 2025-09-29 2025-09-29 0002079272 us-gaap:CommonStockMember 2026-09-30 0002079272 us-gaap:PreferredStockMember 2026-09-30 0002079272 labt:NasdaqCapitalMarketMember 2026-04-23 2026-04-23 0002079272 labt:NasdaqCapitalMarketMember 2026-04-23 0002079272 2026-04-21 2026-04-21 0002079272 labt:ClinicalResearchOrganizationAgreementMember 2026-09-30 0002079272 labt:ClinicalResearchOrganizationAgreementMember 2026-01-01 2026-09-30 0002079272 labt:ClinicalServicesAgreementsMember 2026-01-01 2026-09-30 0002079272 labt:ClinicalServicesAgreementsMember 2026-09-30 0002079272 srt:MaximumMember labt:ClinicalServicesAgreementsMember 2026-01-01 2026-09-30 0002079272 srt:MinimumMember labt:ClinicalServicesAgreementsMember 2026-01-01 2026-09-30 0002079272 us-gaap:CommonStockMember labt:ConvertiblePromissoryNotesMember 2026-04-23 2026-04-23 0002079272 labt:ConvertiblePromissoryNotesMember 2026-04-23 2026-04-23 0002079272 labt:ConvertiblePromissoryNotesMember 2026-05-31 0002079272 labt:ConvertiblePromissoryNotesMember 2026-05-01 2026-05-31 0002079272 labt:ShortTermNotesMember 2026-09-30 0002079272 labt:ShortTermPromissoryNotesMember 2026-04-01 2026-04-30 0002079272 labt:ShortTermPromissoryNotesMember 2026-03-01 2026-03-31 0002079272 labt:ShortTermPromissoryNotesMember 2026-02-01 2026-02-28 0002079272 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0002079272 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0002079272 labt:CommonStockWarrantsMember 2025-01-01 2025-09-30 0002079272 labt:CommonStockWarrantsMember 2026-01-01 2026-09-30 0002079272 labt:SeriesBConvertiblePreferredSharesMember 2025-01-01 2025-09-30 0002079272 labt:SeriesAConvertiblePreferredSharesMember 2025-01-01 2025-09-30 0002079272 labt:SeriesBConvertiblePreferredStockMember 2025-01-01 2025-09-30 0002079272 labt:SeriesBConvertiblePreferredStockMember 2025-07-01 2025-09-30 0002079272 labt:Lakewood-AmedexBiotherapeuticsIncMember 2025-09-29 2025-09-29 0002079272 2026-04-23 0002079272 2025-09-30 0002079272 2024-12-31 0002079272 2025-12-31 0002079272 us-gaap:TreasuryStockCommonMember 2026-09-30 0002079272 us-gaap:RetainedEarningsMember 2026-09-30 0002079272 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0002079272 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-09-30 0002079272 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0002079272 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0002079272 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0002079272 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-07-01 2026-09-30 0002079272 2026-06-30 0002079272 us-gaap:TreasuryStockCommonMember 2026-06-30 0002079272 us-gaap:RetainedEarningsMember 2026-06-30 0002079272 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0002079272 us-gaap:CommonStockMember 2026-06-30 0002079272 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-06-30 0002079272 2026-04-01 2026-06-30 0002079272 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0002079272 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0002079272 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0002079272 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-04-01 2026-06-30 0002079272 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0002079272 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0002079272 2026-03-31 0002079272 us-gaap:TreasuryStockCommonMember 2026-03-31 0002079272 us-gaap:RetainedEarningsMember 2026-03-31 0002079272 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0002079272 us-gaap:CommonStockMember 2026-03-31 0002079272 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0002079272 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0002079272 2026-01-01 2026-03-31 0002079272 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0002079272 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0002079272 us-gaap:TreasuryStockCommonMember 2025-12-31 0002079272 us-gaap:RetainedEarningsMember 2025-12-31 0002079272 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0002079272 us-gaap:CommonStockMember 2025-12-31 0002079272 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0002079272 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0002079272 us-gaap:TreasuryStockCommonMember 2025-09-30 0002079272 us-gaap:RetainedEarningsMember 2025-09-30 0002079272 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0002079272 us-gaap:CommonStockMember 2025-09-30 0002079272 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0002079272 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0002079272 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0002079272 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0002079272 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0002079272 2025-06-30 0002079272 us-gaap:TreasuryStockCommonMember 2025-06-30 0002079272 us-gaap:RetainedEarningsMember 2025-06-30 0002079272 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0002079272 us-gaap:CommonStockMember 2025-06-30 0002079272 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0002079272 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0002079272 2025-04-01 2025-06-30 0002079272 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0002079272 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0002079272 2025-03-31 0002079272 us-gaap:TreasuryStockCommonMember 2025-03-31 0002079272 us-gaap:RetainedEarningsMember 2025-03-31 0002079272 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0002079272 us-gaap:CommonStockMember 2025-03-31 0002079272 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0002079272 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0002079272 2025-01-01 2025-03-31 0002079272 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0002079272 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0002079272 us-gaap:TreasuryStockCommonMember 2024-12-31 0002079272 us-gaap:RetainedEarningsMember 2024-12-31 0002079272 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0002079272 us-gaap:CommonStockMember 2024-12-31 0002079272 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0002079272 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0002079272 labt:SeriesCConvertiblePreferredStockMember 2025-12-31 0002079272 labt:SeriesBConvertiblePreferredStockMember 2025-12-31 0002079272 labt:SeriesBConvertiblePreferredStockMember 2026-09-30 0002079272 labt:SeriesAConvertiblePreferredStockMember 2025-12-31 0002079272 labt:SeriesAConvertiblePreferredStockMember 2026-09-30 0002079272 us-gaap:RelatedPartyMember 2025-12-31 0002079272 2026-11-13 0002079272 labt:SeriesAConvertiblePreferredSharesMember 2026-01-01 2026-09-30 0002079272 labt:SeriesBConvertiblePreferredSharesMember 2026-01-01 2026-09-30 0002079272 labt:ConvertiblePromissoryNotesMember 2026-01-01 2026-09-30 0002079272 labt:ShortTermPromissoryNotesMember 2026-01-01 2026-09-30 0002079272 2025-01-01 2025-12-31 0002079272 us-gaap:RelatedPartyMember 2026-09-30 0002079272 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-09-30 0002079272 us-gaap:TreasuryStockCommonMember 2026-04-01 2026-06-30 0002079272 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0002079272 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0002079272 us-gaap:TreasuryStockCommonMember 2026-07-01 2026-09-30 0002079272 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0002079272 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0002079272 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0002079272 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0002079272 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-07-01 2025-09-30 0002079272 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0002079272 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0002079272 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0002079272 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-01-01 2026-03-31 0002079272 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0002079272 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0002079272 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2024-12-31 0002079272 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-03-31 0002079272 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-06-30 0002079272 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2025-12-31 0002079272 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2026-03-31 0002079272 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0002079272 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 iso4217:USD xbrli:shares xbrli:shares iso4217:USD xbrli:pure labt:Segments

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________ to ___________

 

Commission File Number: 001-43239

 

LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada   20-5274304
State or Other Jurisdiction of
Incorporation or Organization  
  I.R.S. Employer
Identification No.
     
8031 Cooper Creek Blvd., Unit 103
University Park, Florida
  34201
Address of Principal Executive Offices   Zip Code

 

(941) 225-2515

Registrant’s Telephone Number, Including Area Code

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   LABT   NASDAQ

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

Number of shares of common stock outstanding as of November 13, 2026 was 8,950,088.

 

 

 

 

 

NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In particular, statements contained in this Quarterly Report on Form 10-Q, including but not limited to, statements regarding the sufficiency of our cash, our ability to finance our operations and business initiatives and obtain funding for such activities; our future results of operations and financial position, business strategy and plan prospects, or costs and objectives of management for future acquisitions, are forward looking statements. These forward-looking statements relate to our future plans, objectives, expectations and intentions and may be identified by words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “seeks,” “goals,” “estimates,” “predicts,” “potential” and “continue” or similar words. Readers are cautioned that these forward-looking statements are based on our current beliefs, expectations and assumptions and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those identified under “Risk Factors” in our Registration Statement on Form S-1 (File No. 333-292664), as amended, and elsewhere in this Quarterly Report on Form 10-Q. Therefore, actual results may differ materially and adversely from those expressed, projected or implied in any forward-looking statements. We undertake no obligation to revise or update any forward-looking statements for any reason.

 

NOTE REGARDING COMPANY REFERENCES

 

Throughout this Quarterly Report on Form 10-Q, “Lakewood-Amedex,” the “Company,” “we,” “us” and “our” refer to Lakewood-Amedex Biotherapeutics Inc.

 

 

 

FORM 10-Q

 

TABLE OF CONTENTS

 

    Page
  PART I-FINANCIAL INFORMATION 1
Item l. Condensed Unaudited Financial Statements 1
  Condensed Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025 1
  Condensed Statements of Operations (Unaudited) for the three and nine months ended September 30, 2026 and 2025 2
  Condensed Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited) for the three and nine months ended September 30, 2026 and 2025 3
  Condensed Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2026 and 2025 4
  Notes to the Condensed Financial Statements 5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 19
Item 3. Quantitative and Qualitative Disclosures About Market Risk 26
Item 4. Controls and Procedures 26
     
  PART II-OTHER INFORMATION 27
Item 1. Legal Proceedings 27
Item 1A. Risk Factors 27
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27
Item 3. Defaults Upon Senior Securities 27
Item 4. Mine Safety Disclosures 27
Item 5. Other Information 27
Item 6. Exhibits 28
SIGNATURES 30

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Condensed Unaudited Financial Statements

 

LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.

CONDENSED BALANCE SHEETS

 

    As of
September 30,
2026
    As of
December 31,
2025
 
    (Unaudited)        
ASSETS            
Current assets:            
Cash and cash equivalents   $ 2,823,636     $ 236,400  
Investments     500,000       —  
Interest receivable     5,532       —  
Prepaid expenses and other current assets     185,447       68,989  
Total current assets     3,514,615       305,389  
                 
Operating lease right-of-use asset     70,234       158,852  
Property and equipment, net     5,749       9,225  
Other assets     7,821       8,132  
Total assets   $ 3,598,419     $ 481,598  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)                
Current liabilities:                
Accounts payable   $ 240,397     $ 381,041  
Accrued expenses and other current liabilities     361,460       303,872  
Accrued interest – related parties     —       100,881  
Operating lease liability – current portion     71,433       119,306  
Notes payable – related parties     —       1,500,000  
Total current liabilities     673,290       2,405,100  
                 
Operating lease liability, net of current portion     —       41,035  
Total liabilities     673,290       2,446,135  
                 
Commitments and Contingencies                
                 
Stockholders’ equity (deficit):                
Series A convertible preferred stock, voting, $0.0001 par value, 8,000,000 shares authorized; 0 and 6,590,045 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively.     —       659  
Series B convertible preferred stock, voting, $0.0001 par value, 52,500,000 shares authorized; 0 and 23,811,426 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively.     —       2,381  
Series C convertible preferred stock, voting, $0.0001 par value, 937,500 shares authorized; 322,240 and 0 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively.     32       —  
Common stock, $0.0001 par value, 12,500,000 shares authorized; 3,664,475 issued and 3,659,688 outstanding at September 30, 2026; 704,435 issued and 699,648 outstanding at December 31, 2025.     366       70  
Additional paid-in capital     73,189,458       51,533,483  
Accumulated deficit     (70,114,727 )     (53,351,130 )
Treasury stock, 4,787 shares, at cost, at September 30, 2026 and December 31, 2025.     (150,000 )     (150,000 )
Total stockholders’ equity (deficit)     2,925,129       (1,964,537 )
Total liabilities and stockholders’ equity (deficit)   $ 3,598,419     $ 481,598  

 

The accompanying notes are an integral part of these condensed financial statements.

 

1

 

 

LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.
CONDENSED STATEMENTS OF OPERATIONS

 

    For the Three Months Ended
September 30,
    For the Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
    (Unaudited)     (Unaudited)     (Unaudited)     (Unaudited)  
Revenue   $ —     $ —     $ —     $ —  
                                 
Operating expenses:                                
Research and development     733,096       752,931       1,418,263       1,069,536  
General and administrative     776,476       1,126,227       4,765,403       1,987,298  
Depreciation     1,159       1,159       3,476       3,476  
Total operating expenses     1,510,731       1,880,317       6,187,142       3,060,310  
                                 
Loss from operations     (1,510,731 )     (1,880,317 )     (6,187,142 )     (3,060,310 )
                                 
Other income (expense):                                
Interest income     36,000       10,966       65,364       20,664  
Interest expense     —       (37,808 )     (48,852 )     (63,073 )
Other income     —       —       600       —  
Total other income (expense), net     36,000       (26,842 )     17,112       (42,409 )
                                 
Net loss   $ (1,474,731 )   $ (1,907,159 )   $ (6,170,030 )   $ (3,102,719 )
                                 
Basic and diluted net loss per common share   $ (0.62 )   $ (3.46 )   $ (4.50 )   $ (6.61 )
                                 
Weighted average number of common shares outstanding, basic and diluted     2,386,287       696,880       1,508,079       695,269  

 

The accompanying notes are an integral part of these condensed financial statements.

 

2

 

 

LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) (UNAUDITED)

 

    Series A
Preferred Stock
    Series B
Preferred Stock
    Series C
Preferred Stock
    Common Stock     Additional
Paid-in
    Accumulated     Treasury Stock     Total
Stockholders’
Equity
 
    Shares     Amount     Shares     Amount     Shares     Amount     Shares     Amount     Capital     Deficit     Shares     Amount     (Deficit)  
                                                                               
Balance at January 1, 2025     6,590,045     $ 659       23,811,426     $ 2,381       —     $ —       699,237     $ 70     $ 50,059,994     $ (49,503,493 )     (4,787 )   $ (150,000 )   $ 409,611  
Stock-based compensation     —       —       —       —       —       —       —       —       53,773       —       —       —       53,773  
Net loss     —       —       —       —       —       —       —       —       —       (539,617 )     —       —       (539,617 )
Balance at March 31, 2025     6,590,045       659       23,811,426       2,381       —       —       699,237       70       50,113,767       (50,043,110 )     (4,787 )     (150,000 )     (76,233 )
Stock-based compensation     —       —       —       —       —       —       —       —       48,925       —       —       —       48,925  
Net loss     —       —       —       —       —       —       —       —       —       (655,943 )     —       —       (655,943 )
Balance at June 30, 2025     6,590,045     $ 659       23,811,426     $ 2,381       —     $ —       699,237     $ 70     $ 50,162,692     $ (50,699,053 )     (4,787 )   $ (150,000 )   $ (683,251 )
Stock issued to directors     —       —       —       —       —       —       5,198       —       120,000       —       —       —       120,000  
Stock-based compensation     —       —       —       —       —       —       —       —       1,204,094       —       —       —       1,204,094  
Net loss     —       —       —       —       —       —       —       —       —       (1,907,159 )     —       —       (1,907,159 )
Balance at September 30, 2025     6,590,045     $ 659       23,811,426     $ 2,381       —     $ —       704,435     $ 70     $ 51,486,786     $ (52,606,212 )     (4,787 )   $ (150,000 )   $ (1,266,316 )
                                                                                                         
Balance at January 1, 2026     6,590,045     $ 659       23,811,426     $ 2,381       —     $ —       704,435     $ 70     $ 51,533,483     $ (53,351,130 )     (4,787 )   $ (150,000 )   $ (1,964,537 )
Stock-based compensation     —       —       —       —       —       —       —       —       46,180       —       —       —       46,180  
Net loss     —       —       —       —       —       —       —       —       —       (923,291 )     —       —       (923,291 )
Balance at March 31, 2026     6,590,045       659       23,811,426       2,381       —       —       704,435       70       51,579,663       (54,274,421 )     (4,787 )     (150,000 )     (2,841,648 )
Issuance of Series C Preferred Stock, net of issuance costs of $697,905     —       —       —       —       937,500       94       —       —       6,802,001       —       —       —       6,802,095  
Conversion of Series A Preferred Stock     (6,590,045 )     (659 )     —       —       —       —       111,358       11       648       —       —       —       —  
Conversion of Series B Preferred Stock into common stock     —       —       (23,811,426 )     (2,381 )     —       —       402,226       40       2,341       —       —       —       —  
Series B Preferred Stock accumulated dividends accrued     —       —       —       —       —       —       —       —       —       (10,593,567 )     —       —       (10,593,567 )
Conversion of accrued Series B Preferred Stock dividends into common stock     —       —       —       —       —       —       170,425       17       10,593,550       —       —       —       10,593,567  
Conversion of convertible notes and accrued interest into common stock     —       —       —       —       —       —       20,600       2       1,647,317       —       —       —       1,647,319  
Conversion of Series C Preferred Stock for common stock     —       —       —       —       (440,343 )     (44 )     737,011       74       (30 )     —       —       —       —  
Stock issued for professional services     —       —       —       —       —       —       27,931       3       2,434,077       —       —       —       2,434,080  
Stock-based compensation     —       —       —       —       —       —       —       —       61,245       —       —       —       61,245  
Net loss     —       —       —       —       —       —       —       —       —       (3,772,008 )     —       —       (3,772,008 )
Balance at June 30, 2026     —     $ —       —     $ —       497,157     $ 50       2,173,986     $ 217     $ 73,120,812     $ (68,639,996 )     (4,787 )   $ (150,000 )   $ 4,331,083  
Conversion of Series C Preferred Stock for common stock     —       —       —       —       (174,917 )     (18 )     1,490,489       149       (131 )     —       —       —       —  
Stock-based compensation     —       —       —       —       —       —       —       —       68,777       —       —       —       68,777  
Net loss     —       —       —       —       —       —       —       —       —       (1,474,731 )     —       —       (1,474,731 )
Balance at September 30, 2026     —     $ —       —     $ —       322,240     $ 32       3,664,475     $ 366     $ 73,189,458     $ (70,114,727 )     (4,787 )   $ (150,000 )   $ 2,925,129

 

The accompanying notes are an integral part of these condensed financial statements.

 

3

 

 

LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.

CONDENSED STATEMENTS OF CASH FLOWS

 

    For the Nine Months Ended
September 30,
 
    2026     2025  
    (Unaudited)     (Unaudited)  
Cash flows from operating activities:            
Net loss   $ (6,170,030 )   $ (3,102,719 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation     3,476       3,476  
Stock-based compensation     176,202       1,306,792  
Amortization of right-of-use asset     88,618       86,210  
Issuance of common stock for professional services     2,434,080       —  
Changes in operating assets and liabilities:                
Prepaid expenses and other assets     (121,679 )     (26,911 )
Accounts payable     (140,644 )     112,307  
Accrued expenses and other current liabilities     57,588       118,928  
Accrued interest - related parties     46,438       63,073  
Operating lease liability     (88,908 )     (83,844 )
Net cash used in operating activities     (3,714,859 )     (1,522,688 )
                 
Cash flows from investing activities:                
Purchase of investments     (2,250,000 )     —  
Proceeds from maturities of investments     1,750,000       —  
Net cash used in investing activities     (500,000 )     —  
                 
Cash flows from financing activities:                
Proceeds from issuance of Series C Convertible Preferred Stock, net of issuance costs of $697,905     6,802,095       —  
Proceeds from notes payable - related parties     168,158       1,500,000  
Proceeds from notes payable – other     30,000       —  
Repayment of notes payable - related parties     (168,158 )     —  
Repayment of notes payable - other     (30,000 )     —  
Net cash provided by financing activities     6,802,095       1,500,000  
                 
Net increase (decrease) in cash and cash equivalents     2,587,236       (22,688 )
Cash and cash equivalents - beginning of period     236,400       681,098  
Cash and cash equivalents - end of period   $ 2,823,636     $ 658,410  
                 
Supplemental disclosure of cash flow information:                
Cash paid during the nine months ended for:                
Interest   $ 2,409     $ —  
                 
Non-cash investing and financing activities:                
Conversion of convertible notes payable into common stock   $ 1,500,000     $ —  
Conversion of convertible notes payable accrued interest into common stock   $ 147,319     $ —  
Common stock issued to board members for settlement of accrued board fees   $

—

    $

120,000

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

4

 

 

LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.

Notes to Condensed Financial Statements (Unaudited)

 

NOTE 1 – ORGANIZATION, BASIS OF PRESENTATION AND LIQUIDITY

 

Lakewood-Amedex Biotherapeutics Inc. (“Lakewood-Amedex” or the “Company”) is a Nevada corporation headquartered in University Park, Florida. The Company was originally incorporated on July 11, 2006 under the name Nu Pharmas, Inc. and redomiciled from Delaware to Nevada in June 2025.

 

The Company is a clinical-stage biotechnology company focused on the development of novel antimicrobial therapeutics for the treatment of serious infectious diseases, including infections caused by antibiotic-resistant bacteria. The Company’s product candidates are designed for localized delivery to the site of infection for the treatment of both acute and chronic infectious diseases.

 

As of September 30, 2026, the Company owned 71 issued patents and had 45 pending patent applications covering its product candidates and related technologies.

 

The Company’s lead product candidate, Nu-3 (Bisphosphocin® gel formulation), is being developed as a topical antimicrobial therapy for the treatment of infections in diabetic foot ulcers. The Company has completed a Phase 1 safety study and an exploratory Phase 2 clinical trial of Nu-3 and in September 2026, dosed the first patient in a Phase 2a dose-comparison clinical trial to evaluate dosing and administration for the treatment of mildly infected diabetic foot ulcers (“iDFU”). The Company is also continuing preclinical development activities for additional antimicrobial product candidates.

 

On April 23, 2026, the Company’s common stock commenced trading on the Nasdaq Capital Market under the ticker symbol LABT.

 

Liquidity and Going Concern Considerations

 

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Accordingly, the accompanying financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

The Company incurred a net loss of approximately $6.2 million for the nine months ended September 30, 2026 and used approximately $3.7 million in net cash from operating activities during the same period. The Company has historically incurred recurring operating losses and negative operating cash flows and expects to continue to incur operating losses and consume cash as it executes its business plan. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed financial statements are issued.

 

During the nine months ended September 30, 2026, the Company completed the issuance of 937,500 shares of Series C Convertible Preferred Stock (“Series C Financing”) for aggregate gross proceeds of approximately $7.5 million and net proceeds of approximately $6.8 million after deducting placement agent commissions and other offering costs. In addition, the Company repaid in full all short-term promissory notes issued during April 2026, together with accrued interest, using a portion of the proceeds from the financing.

 

On April 23, 2026, the Company completed its direct listing on the Nasdaq Capital Market. In connection with the listing, all outstanding convertible promissory notes with an aggregate principal balance of approximately $1.5 million, together with accrued interest thereon, automatically converted into shares of the Company’s common stock in accordance with their terms. In addition, all outstanding shares of the Company’s Series A Convertible Preferred Stock (“Series A Preferred”) and Series B Convertible Preferred Stock (“Series B Preferred”), including all accumulated and unpaid Series B dividends, automatically converted into shares of the Company’s common stock in accordance with their terms.

 

5

 

 

Management believes that the net proceeds from the Series C Financing, together with the elimination of outstanding debt obligations through the automatic conversions completed in connection with the Nasdaq listing, have significantly improved the Company’s balance sheet and improved its near-term liquidity. However, based on its current operating plan, management expects that the Company’s existing cash, cash equivalents and certificates of deposit will be sufficient liquidity to fund operations through January 2027.

 

The Company will require additional capital to fund operations beyond that period and to execute its long-term business plan. Accordingly, management intends to pursue additional capital through one or more equity financings, debt financings, strategic partnerships, licensing arrangements, government grants or other financing alternatives. There can be no assurance that such financing will be available on acceptable terms, or at all.

 

Because the Company will require additional financing within one year after the date these condensed financial statements are issued and such financing is not considered probable under the provisions of ASC 205-40, management has concluded that its plans do not alleviate the substantial doubt about the Company’s ability to continue as a going concern. 

 

Interim Financial Information

 

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual financial statements.

 

The condensed balance sheet as of September 30, 2026 and the condensed statements of operations and stockholders’ equity (deficit) for the three and nine months ended September 30, 2026 and 2025, and condensed statements of cash flows for the nine months ended September 30, 2026 and 2025 are unaudited. The balance sheet as of December 31, 2025 has been derived from the audited financial statements as of that date but does not include all disclosures required by U.S. GAAP for annual financial statements. These condensed financial statements should be read in conjunction with the Company’s audited financial statements and related notes as of and for the year ended December 31, 2025 included in the Company’s Registration Statement on Form S-1, as amended.

 

In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial condition as of September 30, 2026 and results of its operations and cash flows for the interim periods presented. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year ending December 31, 2026 or for any future interim period.

 

Comparative Amounts

 

Certain share and per share amounts presented in these condensed financial statements have been retroactively adjusted to reflect the one-for-ten reverse stock split that became effective on June 19, 2026, as described in Note 6. As a result, certain share and per share amounts previously reported for prior periods have been revised to conform to the current presentation.  

 

NOTE 2 –SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

 

The preparation of the accompanying unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying condensed financial statements and related disclosures. Significant estimates include, but are not limited to, the valuation of stock-based compensation awards, the assessment of deferred tax assets and related valuation allowances, lease-related assumptions, including the determination of the incremental borrowing rate used in measuring lease liabilities and right-of-use assets, and other estimates and assumptions used in the preparation of the accompanying condensed financial statements.

 

6

 

 

Management bases its estimates on historical experience and on various other factors believed to be reasonable under the circumstances. Actual results could differ materially from those estimates. Management reviews its estimates on an ongoing basis, and revisions are recognized in the period in which the facts and circumstances giving rise to the revisions become known.

 

Concentrations of Credit Risk

 

The Company maintains cash balances with financial institutions and invests a portion of its excess cash in certificates of deposit that are presented as investments in the accompanying condensed balance sheet. Cash deposits and investments may, from time to time, exceed federally insured limits.

 

The Company’s investment policy is designed to preserve principal and manage credit risk by diversifying certificate of deposit investments among multiple financial institutions, with individual certificates generally limited to approximately the applicable Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not historically experienced any losses on its cash deposits or certificates of deposit. Based on its investment policy and the financial institutions with which it maintains its deposits and investments, management believes that the Company is not exposed to significant concentrations of credit risk.

 

Fair Value Measurements

 

The Company follows the provisions of ASC 820, Fair Value Measurement, which establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

ASC 820 establishes a three-level hierarchy for inputs used in measuring fair value:

 

  ● Level 1 – Quoted prices in active markets for identical assets or liabilities.

 

  ● Level 2 – Observable inputs other than quoted prices included within Level 1, including quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and other observable market data.

 

  ● Level 3 – Unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability.

 

The carrying amounts of cash and cash equivalents, interest receivable, accounts payable, accrued expenses and other current liabilities approximate fair value because of the short-term nature of these instruments.

 

At September 30, 2026, the Company held approximately $0.5 million of certificates of deposit with original maturities greater than 90 days and less than a year, which are presented as investments in the accompanying condensed balance sheet and are carried at amortized cost, which approximates fair value due to short-term nature. Interest receivable on these investments is presented separately in the accompanying condensed balance sheet. The estimated fair value would be categorized within Level 2 of the fair value hierarchy.

 

There were no transfers between Level 1, Level 2 or Level 3 during the nine months ended September 30, 2026 or 2025.

 

7

 

 

Preferred Stock

 

The Company accounts for its preferred stock in accordance with the applicable provisions of ASC 480, Distinguishing Liabilities from Equity, ASC 480-10-S99 and ASC 815, Derivatives and Hedging. Preferred stock that is mandatorily redeemable is classified as a liability. Preferred stock that is conditionally redeemable or redeemable upon events not solely within the Company’s control is classified as temporary equity. Preferred stock that is neither mandatorily redeemable nor conditionally redeemable is classified as permanent equity.

 

The Company’s outstanding Series C Convertible Preferred Stock is classified within stockholders’ equity because it is not mandatorily redeemable and the Company concluded that its embedded conversion and other features do not require separate accounting as derivative instruments under ASC 815.

 

Net Loss per Common Share

 

The Company computes earnings per share (“EPS”) in accordance with ASC 260-10 issued by the Financial Accounting Standards Board.

 

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period.

 

Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Because the Company reported a net loss for each period presented, all potentially dilutive securities were anti-dilutive and, accordingly, diluted net loss per common share equals basic net loss per common share.

 

The following tables reconcile net loss to net loss attributable to common stockholders:

 

    For the Three Months Ended
September 30,
 
    2026     2025  
             
Net loss   $ 1,474,731     $ 1,907,159  
Series B cumulative dividends     —       504,150  
Net loss attributable to common stockholders   $ 1,474,731     $ 2,411,309  

 

    For the Nine Months Ended
September 30,
 
    2026     2025  
             
Net loss   $ 6,170,030     $ 3,102,719  
Series B cumulative dividends     619,228       1,496,010  
Net loss attributable to common stockholders   $ 6,789,258     $ 4,598,729  

 

Subsequent to the filing of the Company’s financial statements for the three and nine months ended September 30, 2025, management identified an error in the calculation of net loss attributable to common stockholders used in determining basic and diluted loss per share. The error resulted from the omission of undeclared dividends on the Series B Convertible Preferred Stock of $504,150 and $1,496,010 for the three and nine months ended September 30, 2025, respectively. The amounts presented in the table above have been revised to reflect the correct net loss attributable to common stockholders for those periods.

 

8

 

 

The following potential dilutive securities were excluded from the computation of diluted net loss per common share because their effect would have been anti-dilutive:

 

    September 30,
2026
    September 30,
2025
 
             
Series A convertible preferred shares     —       111,358  
Series B convertible preferred shares including the cumulative dividends     —       554,572  
Common stock warrants     30,076       26,697  
Stock options     126,988       126,988  
Total potentially dilutive shares     157,064       819,615  

 

The Company has outstanding Series C convertible preferred shares that are convertible into common stock at a conversion rate determined by the market price of the Company’s common stock on the conversion date as described under the terms of the agreement. Because the conversion rate is variable, the number of shares issuable upon conversion cannot be determined until the conversion date. These securities were excluded from the table above and the computation of diluted net loss per share for the period presented because their inclusion would have been anti-dilutive.

 

Subsequent to the filing of the Company’s financial statements for the three and nine months ended September 30, 2025, management identified that the potentially dilutive securities included in the table above had not been adjusted for the 1-for-5.92 reverse stock split that became effective on September 29, 2025. The comparative amounts have been revised to correct the total potentially dilutive securities as of September 30, 2025.

 

Research and Development Costs

 

Research and development costs are expensed as incurred. Research and development reimbursements are recorded by the Company as a reduction of research and development costs. The Company incurred research and development costs of $733,096 and $1,418,263 for the three and nine months ended September 30, 2026, respectively, and $752,931 and $1,069,536 for the three and nine months ended September 30, 2025, respectively.

 

Recent Accounting Pronouncements

 

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 requires public business entities to provide additional disclosures about certain expense captions presented on the face of the income statement, including disaggregation of specified natural expense categories in interim and annual reporting periods. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU 2024-03 will have on its financial statement disclosures.

 

In December 2025, the FASB issued ASU 2025-12, Codification Improvements. The amendments address various topics in the Accounting Standards Codification to clarify guidance, correct errors and make other incremental improvements to U.S. GAAP. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The Company is evaluating the effect, if any, that adoption of this guidance will have on its financial statements and related disclosures.

 

In April 2026, the FASB issued ASU 2026-01, Equity (Topic 505): Initial Measurement of Paid-in-Kind Dividends on Equity-Classified Preferred Stock. The amendments establish guidance for the initial measurement of paid-in-kind dividends on equity-classified preferred stock. The amendments are effective for annual reporting periods beginning after December 15, 2026, including interim periods within those annual reporting periods, with early adoption permitted. The Company is currently evaluating the impact that adoption of this guidance will have on its financial statements and related disclosures.

 

NOTE 3 – INVESTMENTS

 

At September 30, 2026, the Company held certificates of deposit with an aggregate carrying value of $500,000, which are classified as investments in the accompanying condensed balance sheet. The certificates of deposit have original maturities greater than 90 days but mature within one year of purchase. Accordingly, they are not classified as cash equivalents.

 

The Company’s investment portfolio consists of multiple bank-issued certificates of deposit purchased through a brokerage account. The certificates of deposit are carried at amortized cost, which approximates fair value due to their relatively short maturities. Accrued interest is recorded separately as interest receivable.

 

Interest earned on the certificates of deposit is recognized as interest income in the accompanying condensed statements of operations.

 

The Company held no investments at December 31, 2025.

 

9

 

 

NOTE 4 – NOTES PAYABLE – RELATED PARTIES

 

Short-Term Promissory Notes

 

During February, March and April 2026, the Company issued unsecured short-term promissory notes to certain existing shareholders and a director in the aggregate principal amount of $168,158 for working capital purposes. The notes bore interest at 12% per annum and were repayable upon the earlier of the closing of the Company’s Series C Convertible Preferred Stock financing or their stated maturity dates.

 

On April 21, 2026, following the closing of the Company’s Series C Convertible Preferred Stock financing, all outstanding short-term promissory notes, together with accrued interest thereon, were repaid in full. Accordingly, no short-term promissory notes were outstanding as of September 30, 2026.

 

Convertible Promissory Notes

 

During May 2025, the Company issued convertible promissory notes in the aggregate principal amount of $1,500,000 to existing investors, members of management and directors to provide interim working capital pending the Company’s anticipated direct listing on the Nasdaq Capital Market. The notes bore interest at 10% per annum and provided for the automatic conversion of all outstanding principal and accrued interest into shares of the Company’s common stock upon the Company’s Nasdaq listing.

 

On April 23, 2026, in connection with the Company’s direct listing on the Nasdaq Capital Market, all outstanding convertible promissory notes, together with accrued and unpaid interest totaling approximately $147,000, automatically converted into an aggregate of 20,600 shares of the Company’s common stock in accordance with their terms. As a result of the conversion, no convertible promissory notes remained outstanding as of September 30, 2026.

 

The Company recorded interest expense related to notes payable of $0 and $48,852 for the three and nine months ended September 30, 2026, respectively, and $37,808 and $63,073 for the three and nine months ended September 30, 2025, respectively. Interest expense is included in other income (expense) in the accompanying condensed statements of operations. 

 

NOTE 5 – COMMITMENTS AND CONTINGENCIES

 

Lease Agreement

 

On November 3, 2021, the Company signed a lease for new office space which commenced April 15, 2022, at University Park, Florida. The lease has an initial term of five years and an option to extend for an additional five years, with an annual base rent at inception of $93,852, annual common area maintenance charges of $15,444, proportionate share of real estate taxes estimated at $6,890 annually plus sales tax of $7,552. The base rent and common area maintenance charges increase three percent (3%) each of the following four years. The Company’s proportionate share of real estate taxes and sales taxes are accounted for as variable lease payments and amounted to $2,399 and $2,719 for the three months ended September 30, 2026 and 2025, respectively, and $7,198 and $8,127 for the nine months ended September 30, 2026 and 2025, respectively.

 

Rent expense was $32,714 and $100,600 for the three and nine months ended September 30, 2026, respectively, and $35,338 and $101,375 for the three and nine months ended September 30, 2025, respectively. These amounts are included in general and administrative expenses in the accompanying condensed statements of operations.

 

10

 

 

At September 30, 2026, the remaining lease term and discount rate were 0.6 years and 2.79%, respectively.

 

Maturity of operating lease liability at September 30, 2026 is as follows:

 

Year Ending December 31,      
2026 (remaining)   $ 30,753  
2027     41,179  
Total lease payments     71,932  
Less: Interest     (499 )
Present value of lease liability   $ 71,433  

 

Clinical Services Agreements

 

During the second quarter of 2026, the Company entered into and committed to certain clinical manufacturing and clinical research agreements in support of its Phase 2a clinical trial for its Nu-3 topical gel product candidate. Costs incurred under these agreements are recognized as research and development expense as the related services are performed.

 

In May 2025, the Company received a proposed statement of work from Pace Life Sciences (“Pace”) related to the cGMP clinical manufacturing of the Company’s Nu-3 topical gel product candidate. During 2025, the Company did not commit to the full manufacturing program and was obligated only for limited preliminary supplies that were ordered and paid for during the period.

 

On April 23, 2026, the Company authorized and committed to proceed with the full clinical manufacturing program with Pace in support of the Company’s planned clinical development activities. Pursuant to the statement of work, Pace will provide cGMP clinical manufacturing services for Nu-3 topical gel-filled applicators, including Phase A – cGMP clinical manufacturing, Phase B – labeling and kitting of Nu-3 applicators, and Phase C – an 18-month International Council for Harmonisation (“ICH”) stability program.

 

The statement of work provides for fixed contractual fees totaling $197,125 for the Phase A, Phase B and Phase C activities, which are invoiced based on specified project milestones. In addition, the Company is responsible for pass-through costs, including materials, supplies, shipping, irradiation, outsourced testing, stability storage and other project-related expenses, which are billed at cost plus 15% and are currently estimated at 40% to 45% of the fixed contractual fees. Pace may also invoice additional out-of-scope services, including document revisions, raw data packages, investigations and retesting, at contractual hourly rates. The agreement may be terminated by either party under customary termination provisions; however, in the event of cancellation prior to completion, the Company remains responsible for payment of all completed work and work in process through the termination date.

 

Through September 30, 2026, the Company had incurred costs of $193,367 under the agreement, consisting of $143,125 related to the Phase A, Phase B and Phase C contractual activities and $50,242 of pass-through costs. Based on the current statement of work, the Company expects to incur additional costs to complete the project, although the ultimate amount will depend on the actual pass-through costs incurred and any approved changes in the scope of work.

 

On April 21, 2026, the Company entered into a Clinical Research Organization Agreement with Professional Education and Research Institute, LLC (“PERI”) in connection with the Company’s Phase 2a clinical trial of Nu-3 for the treatment of iDFU. Pursuant to the agreement, PERI will provide clinical trial management and operational support services, including trial start-up activities, site feasibility and qualification, site contracting and budgeting, institutional review board coordination, project management, clinical monitoring, site management, electronic data capture oversight, data management, database lock and archive activities, and related clinical and data management services.

 

11

 

 

The agreement provides for professional service fees totaling $507,292, payable based on the achievement of specified project milestones and the performance of services. In addition, the Company expects to incur $466,807 of pass-through costs related to the clinical trial, resulting in an aggregate estimated project cost of $974,099. The agreement may be terminated by either party under customary termination provisions.

 

Through September 30, 2026, the Company had incurred costs of $468,335 under the agreement, consisting of $218,570 for services performed and $249,765 of pass-through costs. Based on the current statement of work, $505,764 of the estimated aggregate project cost remained to be incurred as of September 30, 2026, subject to changes in the scope of services, pass-through costs, and other project-related activities.

 

Advisory and Placement Agency Agreement

 

On February 10, 2025, Lakewood-Amedex Biotherapeutics Inc. executed an agreement with RBW Capital Partners LLC (“RBW”), a division of Dawson James Securities, Inc. (the “BD” and together with RBW, the “Placement Agent”) for the provision of financial advisory and financial placement agency and investment banking services, including assistance in connection with the Company’s listing on the Nasdaq Capital Market and related financing activities.

 

Pursuant to the terms of the agreement, upon closing of a qualified financing transaction, the Company agreed to pay the Placement Agent a cash transaction fee equal to 7.0% of the gross proceeds raised from investors introduced by the placement agent, reimburse certain expenses, and issue shares of the Company’s common stock equal to 1.75% of the Company’s fully diluted common stock outstanding immediately prior to the closing of the Company’s Series C Convertible Preferred Stock financing (the “Advisory Stock”). On March 7, 2025, the parties amended the agreement to provide the Advisory Stock with demand registration rights and to require the Company to file a resale registration statement covering such shares following the Company’s Nasdaq listing.

 

In connection with the closing of the Company’s Series C Convertible Preferred Stock on April 21, 2026, the Company paid the Placement Agent a cash transaction fee of $525,000 and reimbursed offering-related expenses of $150,000, which were recorded as issuance costs. In addition, upon the Company’s listing on the Nasdaq Capital Market on April 23, 2026, the Company issued 27,273 shares of common stock to the Placement Agent representing the advisory shares (the “Advisory Shares”) issued as consideration pursuant to the placement agency agreement and valued at $2,359,080.

 

The agreement was terminated effective August 6, 2026 following the Company’s delivery of written notice on July 8, 2026. The Company has no continuing obligations under the agreement other than those that expressly survive termination.

 

Legal Proceedings

 

There are no matters currently outstanding for which any liabilities have been accrued or require disclosure.

 

NOTE 6 – STOCKHOLDERS’ EQUITY

 

Authorized Stock

 

The Company’s authorized capital stock consists of common stock and preferred stock, each having a par value of $0.0001 per share.

 

The holders of the Company’s Common Stock are entitled to one vote for each share held. The holders of Common Stock are entitled to receive ratably such dividends, if any, as may be declared by the Board of Directors out of legally available funds. The Company has not declared or paid any dividends on its common stock, and it currently intends to retain any future earnings to fund the operation and expansion of its business. Upon liquidation, dissolution or winding-up of the Company, the holders of Common Stock are entitled to share ratably in all assets remaining after payment of all liabilities and any preferential amounts payable to holders of any outstanding preferred stock. The holders of Common Stock have no preemptive, subscription, redemption, or conversion rights. 

 

12

 

 

Common Stock

 

During the nine months ended September 30, 2026, the Company completed its financing through the issuance of Series C Convertible Preferred Stock, effected a reverse stock split, and completed the direct listing of its common stock on the Nasdaq Capital Market, resulting in significant changes to the Company’s capital structure.

 

On September 29, 2025, the Company effected a one-for-5.92 (1:5.92) reverse stock split of its common stock (the “2025 Reverse Split”). The 2025 Reverse Split was approved by the Board of Directors on August 18, 2025 and by the Company’s stockholders by written consent in September 2025. The 2025 Reverse Split was implemented in connection with the Company’s planned listing on the Nasdaq Capital Market and did not affect the number of authorized shares of common stock.

 

On June 19, 2026, the Company effected a one-for-ten (1:10) reverse stock split of its common stock (the “2026 Reverse Split”). The 2026 Reverse Split was approved by the Board of Directors on June 1, 2026 and became effective upon the filing of Articles of Amendment to the Company’s Articles of Incorporation with the Nevada Secretary of State. The amendment effected both the one-for-ten reverse split of the Company’s common stock and a proportional reduction in the number of authorized shares of common stock. The number of authorized shares of preferred stock was not affected.

 

The 2026 Reverse Split was implemented in accordance with the requirements of the Securities Purchase Agreement governing the Company’s Series C Convertible Preferred Stock.

 

Each reverse stock split affected the Company’s issued and outstanding shares of common stock, treasury shares, stock options, warrants and all other securities exercisable for or convertible into common stock on a proportionate basis. No fractional shares were issued in connection with either reverse stock split. Fractional interests resulting from either reverse stock split were rounded up to the nearest whole share.

 

All share and per-share amounts presented in these condensed financial statements and the accompanying notes have been retroactively adjusted to give effect to both the 2025 Reverse Split and the 2026 Reverse Split for all periods presented. The par value of the Company’s common stock and preferred stock was not affected by either reverse stock split.

 

During the nine months ended September 30, 2026, the Company issued 658 shares of Common Stock to its SEC counsel in consideration for legal services provided in connection with the Company’s securities filings and Nasdaq listing. The shares were valued at approximately $75,000 and the amount was recorded as professional fees.

 

On September 22, 2026, the Company’s shareholders approved an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of common stock from 12,500,000 shares to 100,000,000 shares. The Company filed the Articles of Amendment with the Nevada Secretary of State in October 2026, and the amendment became effective upon filing. Accordingly, the increase in authorized common stock occurred subsequent to September 30, 2026.

 

Reserved Shares

 

As of September 30, 2026, the Company has reserved the following shares of common stock for future issuance:

 

Shares reserved for future issuance under the 2020 Equity Incentive Plan     284,838  
Stock options outstanding under the 2020 Equity Incentive Plan     115,162  
Stock options outstanding outside the 2020 Equity Incentive Plan    

11,826

 
Warrants outstanding     30,076  
Issuance upon conversion of Series C Convertible Preferred Stock     3,222,400  
Total     3,664,302  

 

Subsequent to September 30, 2026, as described in Note 10, Subsequent Events, the Company completed the redemption of all 127,097 remaining outstanding shares of Series C Convertible Preferred Stock held by Shakawe Capital LLC for an aggregate payment of $1,270,970. Upon completion of the redemption on November 4, 2026, all remaining shares of Series C Convertible Preferred Stock were cancelled and returned to treasury, and all associated conversion rights were extinguished. Accordingly, no shares of common stock remain reserved for future issuance upon conversion of Series C Convertible Preferred Stock. The 3,222,400 shares reflected in the above schedule represent the potential common shares reserved for conversion as of September 30, 2026, prior to the subsequent redemption.

 

On September 22, 2026, the Company’s shareholders approved an amendment to the Company’s 2020 Equity Incentive Plan to increase the number of shares authorized for issuance under the Plan from 183,505 shares to 400,000 shares. Of the 400,000 shares authorized under the amended Plan, 115,162 shares were subject to outstanding stock options and 284,838 shares remained available for future grants of stock options and other equity-based awards in accordance with the terms of the Plan. The 11,826 outstanding options issued prior to adoption of the 2020 Equity Incentive Plan are not included in the Plan reserve.

 

13

 

 

Series A and Series B Convertible Preferred Stock

 

Immediately prior to the Company’s direct listing on the Nasdaq Capital Market on April 23, 2026, all outstanding shares of Series A Preferred and Series B Preferred automatically converted into shares of the Company’s common stock in accordance with their respective Certificates of Designation.

 

Following the 2026 Reverse Split, the Series A Preferred converted into 111,358 shares of common stock and the Series B Preferred, including the accumulated and unpaid dividends through the conversion date, converted into 572,651 shares of common stock.

 

Following the automatic conversions, no shares of Series A Preferred or Series B Preferred remained issued or outstanding, and all associated conversion rights, dividend rights and liquidation preferences terminated.

 

Series C Convertible Preferred Stock

 

On April 21, 2026, the Company completed the issuance of 937,500 shares of Series C Convertible Preferred Stock (“Series C Preferred”) pursuant to the Securities Purchase Agreement dated January 31, 2026.

 

The Series C Preferred has an aggregate stated value of $9.375 million and was issued at a 20% original issue discount for gross proceeds of $7.5 million. After deducting placement agent commissions and other offering costs, the Company received net proceeds of approximately $6.8 million.

 

Each share of Series C Preferred has a stated value of $10.00 and is convertible, at the option of the holder, into shares of the Company’s common stock at a conversion price equal to the lesser of:

 

  ● $10.00 per share; or

 

  ● 80% of the lowest closing sale price of the Company’s common stock during the five consecutive trading days immediately preceding the applicable conversion date, subject to a minimum conversion price of $1.00 per share.

 

The conversion price is subject to customary adjustments for stock splits, stock dividends, recapitalizations and similar transactions, including the 2026 Reverse Split, as well as certain anti-dilution adjustments provided in the Certificate of Designation.

 

Conversion is subject to a 4.99% beneficial ownership limitation unless waived in accordance with the Certificate of Designation.

 

Holders of the Series C Preferred are entitled to cumulative dividends at the rate of 12% per annum based on the stated value. Dividends are payable monthly, in cash or in kind, if declared by the Board of Directors, beginning six months after the commencement of trading of the Company’s common stock on the Nasdaq Capital Market, and accrue only while the Series C Preferred remains outstanding.

 

14

 

 

Upon any liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined in the Certificate of Designation), holders of the Series C Preferred are entitled to receive, prior to any distribution to holders of common stock, the greater of (i) the stated value of the Series C Preferred or (ii) the amount that would have been payable had the Series C Preferred been converted into common stock immediately prior to such event.

 

The Company evaluated the accounting treatment of the Series C Preferred pursuant to ASC 480, Distinguishing Liabilities from Equity, ASC 480-10-S99 and ASC 815, Derivatives and Hedging. The Company concluded that the Series C Preferred is appropriately classified as permanent equity because it is not mandatorily redeemable and any deemed liquidation events are within the Company’s control. The Company further concluded that none of the embedded features require bifurcation as derivative instruments under ASC 815. Accordingly, the Series C Preferred is classified within stockholders’ equity, net of issuance costs.

 

In connection with the financing, the Company entered into a Registration Rights Agreement pursuant to which it agreed to file a registration statement covering the resale of the shares of common stock issuable upon conversion of the Series C Preferred. During the nine months ended September 30, 2026, the Company filed the required registration statement with the Securities and Exchange Commission.

 

NOTE 7 – STOCK-BASED COMPENSATION

 

In November 2020, the Company adopted the 2020 Equity Incentive Plan (the “2020 Plan”), which became effective in January 2021. The 2020 Plan provides for the grant of stock options and restricted stock awards to employees, directors and non-employee service providers.

 

Awards granted under the 2020 Plan expire no later than ten years from the date of grant. The exercise price of incentive stock options and nonqualified stock options granted under the 2020 Plan may not be less than 100% of the fair market value of the Company’s common stock on the date of grant. Awards generally vest over a four-year service period, although awards may be granted with different vesting provisions. The 2020 Plan initially reserved 183,505 shares of the Company’s common stock for issuance.

 

Options

 

During the three and nine months ended September 30, 2025, the Company granted stock options to certain key employees to purchase a total of 62,840 shares of the Company’s Common Stock at an exercise price of $23.10 per share, pursuant to the terms of their employment agreements. The stock options vested on day of grant and have a ten-year contractual term. The total grant date fair value of the options was $1,156,176, calculated using the Black-Scholes-Merton option pricing model.

 

No stock options were granted during the three and nine months ended September 30, 2026.

 

The Company recognizes stock-based compensation expense related to stock options on a straight-line basis over the requisite service periods of each award. As of September 30, 2026, total unrecognized stock-based compensation expense related to unvested stock options was approximately $113,634 and is expected to be recognized over a weighted-average period of approximately 0.6 year.

 

As of September 30, 2026, options to purchase an aggregate of 126,988 shares of the Company’s common stock were outstanding, of which 115,831 were exercisable.

 

15

 

 

Warrants

 

On April 24, 2026, the Company issued a warrant to purchase 3,379 shares of its common stock to a newly appointed member of the Board of Directors as a component of the director’s compensation. The warrant has an exercise price of $100.00 per share, expires ten years from the date of grant, and vests over a two-year period, with 25% of the underlying shares becoming exercisable on each six-month anniversary of the grant date, subject to the director’s continued service.

 

The Company determined the grant-date fair value of the warrant using the Black-Scholes option pricing model. The resulting fair value is recognized as stock-based compensation expense on a straight-line basis over the requisite service period. As of September 30, 2026, unrecognized stock-based compensation expense related to the unvested director warrant was approximately $143,123 which is expected to be recognized over the remaining requisite service period of approximately 1.6 years.

 

During the three and nine months ended September 30, 2025, warrants to purchase 0 shares and 6,758 shares of common stock, respectively, expired. No warrants were exercised, expired, or forfeited during the three and nine months ended September 30, 2026.

 

As of September 30, 2026, warrants to purchase an aggregate of 30,076 shares of the Company’s common stock were outstanding, of which 26,697 were exercisable.

 

Summary of Stock-Based Compensation Expense

 

The following table presents stock-based compensation expense recognized in the accompanying condensed statements of operations:

 

    For the Three Months Ended
September 30,
 
    2026     2025  
             
Research and development   $ 27,452     $ 581,435  
General and administrative     41,325       622,659  
Total   $ 68,777     $ 1,204,094  

 

    For the Nine Months Ended
September 30,
 
    2026     2025  
             
Research and development   $ 82,356     $ 650,501  
General and administrative     93,846       656,291  
Total   $ 176,202     $ 1,306,792  

 

NOTE 8 – INCOME TAXES

 

The provision for income taxes for interim periods is determined, in accordance with ASC 740-270, Income Taxes—Interim Reporting, using an estimated annual effective tax rate, adjusted for discrete items recognized during the period, if any. Because the Company has historically incurred operating losses and maintains a full valuation allowance against its deferred tax assets, no income tax provision or benefit has been recognized for the periods presented. The estimated annual effective tax rate remains subject to change based on future operating results, changes in valuation allowances against deferred tax assets, changes in tax laws or their interpretation, and the recognition or derecognition of uncertain tax positions, if any.

 

16

 

 

Due to the Company’s cumulative operating losses and resulting full valuation allowance against its deferred tax assets, the Company did not record an income tax provision or benefit for the three and nine months ended September 30, 2026 and 2025. Management has concluded that it is more likely than not that the Company’s deferred tax assets will not be realized.

 

The Company recognizes interest and penalties related to uncertain tax positions, if any, as a component of income tax expense. As of September 30, 2026 and December 31, 2025, the Company had no unrecognized tax benefits and had not accrued any interest or penalties related to uncertain tax positions.

 

NOTE 9 – SEGMENT REPORTING

 

The Company operates as a single operating segment focused on development of novel antimicrobial therapies. As the CODM, our Chief Executive Officer manages our company, reviews operating results, assesses performance and allocates resources on an aggregate basis using total assets and actual expenses compared to net loss. Please refer to the condensed financial statements for further information related to these measures of segment performance.

 

In addition to total assets and actual expenses, the CODM regularly receives disaggregated information regarding research and development expenses, general and administrative expenses, and other segment expenses. Other segment expenses include depreciation and interest expense and are presented net of interest income and other income. 

 

The following tables present the significant expense categories reviewed by the CODM:

 

    For the Three Months Ended
September 30,
 
    2026     2025  
Research and Development            
Clinical and preclinical activities   $ 451,811     $ 32,933  
Personnel     276,282       716,106  
Other     5,003       3,892  
Total research and development     733,096       752,931  
                 
General and Administrative                
Corporate expenses     303,304       144,913  
Personnel     255,099       749,361  
Professional services     180,180       191,788  
Facility costs     37,893       40,165  
Total general and administrative     776,476       1,126,227  
                 
Other Segment (Income) Expenses     (34,841 )     28,001  
                 
Net Loss   $ 1,474,731     $ 1,907,159  

 

    For the Nine Months Ended
September 30,
 
    2026     2025  
Research and Development            
Personnel   $ 704,881     $ 996,339  
Clinical and preclinical activities     698,420       62,044  
Other     14,962       11,153  
Total research and development     1,418,263       1,069,536  
                 
General and Administrative                
Professional services     3,306,376       661,916  
Corporate expenses     698,514       271,706  
Personnel     646,004       938,410  
Facility costs     114,509       115,266  
Total general and administrative     4,765,403       1,987,298  
                 
Other Segment (Income) Expenses     (13,636 )     45,885  
                 
Net Loss   $ 6,170,030     $ 3,102,719  

 

17

 

 

NOTE 10 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the date the financial statements were issued. Based on this evaluation, except for the matters disclosed in Note 6 and as discussed below, there were no material subsequent events requiring recognition or additional disclosure in the accompanying condensed financial statements.

 

On October 14, 2026, the Company entered into a letter agreement with Shakawe Capital LLC (the “Holder”), the holder of all outstanding shares of Series C Preferred, to amend certain terms relating to the Series C Preferred and the related Securities Purchase Agreement.

 

Under the Letter Agreement, the Holder irrevocably and unconditionally waived its rights to all dividends under Section 3.1 of the Certificate of Designation on all Series C Preferred held by the Holder, whether declared or undeclared and regardless of the form of payment, including in connection with liquidation or conversion. The Letter Agreement further provides that the nonpayment of such dividends does not constitute a breach of or default under any transaction document.

 

In addition, the Holder waived its contractual right under Section 4.10 of the Securities Purchase Agreement to require the Company to effect a reverse stock split, including any related remedies for the Company’s failure to effect such a split. The Company retained the right to effect a reverse stock split at its election. The Letter Agreement also amended certain provisions relating to the conversion terms of the Series C Convertible Preferred Stock.

 

Between September 30, 2026 and October 14, 2026, the Holder converted an additional 19,005 shares of Series C Convertible Preferred Stock into 190,050 shares of common stock, leaving 303,235 shares of Series C Convertible Preferred Stock outstanding as of October 14, 2026. From October 15, 2026 through November 2, 2026, the Holder converted an additional 176,138 shares of Series C Convertible Preferred Stock into 5,100,350 shares of common stock. As a result of these conversions, the number of outstanding shares of the Company’s common stock increased from 3,659,688 shares at September 30, 2026 to 8,950,088 shares and 127,097 shares of Series C Convertible Preferred Stock remained outstanding and available for conversion as of November 2, 2026.

 

Subsequent to these conversions, on November 2, 2026, the Company entered into an agreement with the Holder pursuant to which the Company paid aggregate consideration of $1,270,970 to repurchase and cancel all remaining 127,097 shares of Series C Convertible Preferred Stock. Upon completion of the transaction, all remaining Series C Convertible Preferred Stock was retired and cancelled, and all associated conversion rights were extinguished. As a result, no shares of Series C Convertible Preferred Stock remain outstanding, and no additional shares of common stock will be issued upon conversion of Series C Convertible Preferred Stock under the financing arrangement.

 

On November 10, 2026, the Company received a letter from the Listing Qualifications Department (the “Staff”) of Nasdaq notifying the Company that, for the 30 consecutive business days from September 29, 2026 through November 9, 2026, the closing bid price of the Company’s common stock had been below $1.00 per share, the minimum required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

 

Because the Company effected a 1-for-10 reverse stock split on June 22, 2026, within the prior one-year period, the Company is not eligible for a compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv), and the Staff has determined to delist the Company’s securities. Unless the Company requests a hearing by November 17, 2026, trading of the Company’s common stock will be suspended at the opening of business on November 19, 2026, and Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission to remove the Company’s securities from listing and registration on Nasdaq.

 

The Company intends to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”), which will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. At the hearing, the Company intends to present a plan to regain compliance with the Bid Price Rule, which may include a reverse stock split. There can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will regain compliance.

 

18

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis is intended as a review of significant factors affecting our financial condition and results of operations for the periods indicated. The discussion should be read in conjunction with our unaudited condensed financial statements and the notes presented herein included in this Form 10-Q and the audited financial statements and the other information set forth in the S-1 registration statement recently filed with the SEC. ln addition to historical information, the following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties including, but not limited to, those set forth below under “Risk Factors” in our Registration Statement on Form S-1 (File No. 333-292664), as amended, and elsewhere herein. Our actual results could differ significantly from those anticipated in these forward-looking statements as a result of certain factors discussed herein and any other periodic reports filed and to be filed with the Securities and Exchange Commission.

 

Overview

 

Lakewood-Amedex Biotherapeutics Inc. (the “Company”) is a clinical-stage biotechnology company focused on developing a novel class of fast-acting, broad-spectrum antimicrobials known as Bisphosphocins® for the treatment of infectious diseases, including infections caused by antimicrobial-resistant pathogens. The Company’s development programs are focused on advancing its proprietary antimicrobial technology toward potential clinical and commercial applications.

 

The Company’s lead product candidate, Nu-3, is a topical antimicrobial gel being developed for the treatment of mildly infected diabetic foot ulcers (“iDFUs”). In September 2026, the Company achieved an important clinical development milestone when the first patient was dosed in its Phase 2a clinical trial evaluating Nu-3 for this indication. The trial represents a significant step in the Company’s efforts to advance Nu-3 through clinical development and evaluate its potential therapeutic application.

 

The Company’s principal activities include research and development, clinical trial execution, manufacturing and product development, regulatory planning, and the development and protection of its intellectual property portfolio. The Company has not yet generated revenue from commercial product sales and expects to continue incurring substantial research and development and general and administrative expenses as it advances its product candidates and operates as a publicly traded company.

 

The Company has incurred recurring operating losses since inception and expects to continue incurring losses as it advances its clinical development programs. Its future operating results will depend substantially on the progress and results of its clinical trials, the timing and cost of product development, regulatory requirements, and its ability to obtain sufficient capital to fund its operations. Although the financing completed in April 2026 improved the Company’s liquidity, additional financing will be required to support its clinical development programs and ongoing operations. Management continues to evaluate financing alternatives and manage available resources to support the Company’s development plans and other strategic objectives.

 

Recent Developments

 

Advancement of Clinical Development

 

During September 2026, the Company initiated patient dosing in its Phase 2a clinical trial of Nu-3 for the treatment of mildly infected diabetic foot ulcers. The first patient was dosed during the month, marking an important milestone in the advancement of the Company’s clinical development program.

 

The Phase 2a trial is intended to evaluate Nu-3 in patients with iDFUs and generate clinical data to inform the Company’s subsequent development plans. Initiation of patient dosing represents progress from the manufacturing, regulatory, and clinical planning activities undertaken earlier in 2026 toward execution of the Company’s clinical development strategy.

 

The Company expects to incur additional research and development expenses as the trial progresses, including costs associated with clinical trial activities, manufacturing, regulatory matters, and related development requirements. The timing and amount of these expenditures will depend on the progress of the trial and the Company’s subsequent development plans.

 

Annual Meeting of Shareholders

 

On September 22, 2026, the Company held its Annual Meeting of Shareholders. Shareholders approved five proposals: (i) the election of directors to the Company’s Board of Directors; (ii) an amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of common stock from 12.5 million to 100 million; (iii) authorization for the Board of Directors, in its discretion, to effect reverse stock splits of the Company’s outstanding common stock at a ratio not to exceed a cumulative ratio of 1-for-20; (iv) an increase in the number of shares reserved for issuance under the Company’s 2020 Equity Incentive Plan from 183,505 to 400,000 shares; and (v) ratification of the appointment of CBIZ as the Company’s independent registered public accounting firm.

 

Subsequent to the Annual Meeting, in October 2026, the Company filed the amendment to its Articles of Incorporation with the Nevada Secretary of State to effect the increase in authorized common shares from 12.5 million to 100 million. The amendment became effective upon filing. See Note 6 to the Unaudited Condensed Financial Statements.

 

The shareholder approvals provide the Company with additional corporate flexibility with respect to its authorized capital, equity incentive arrangements, and potential future capital structure requirements.

 

19

 

 

Series C Convertible Preferred Stock

 

During the third quarter of 2026, the Company continued to experience conversions of its Series C Convertible Preferred Stock into common stock. These conversions affected the Company’s outstanding preferred stock and common stock capitalization. The terms of the Series C Convertible Preferred Stock in effect as of September 30, 2026, including the applicable conversion price and minimum conversion price, are described in the Notes to the Unaudited Condensed Financial Statements.

 

On October 14, 2026, the Company entered into a letter agreement with the Holder of the outstanding Series C Convertible Preferred Stock, addressing certain rights and terms under the Series C Certificate of Designation and related securities purchase agreement.

 

Under the Letter Agreement, the Holder irrevocably and unconditionally waived its rights to all dividends under Section 3.1 of the Certificate of Designation on all Series C Preferred held by the Holder, whether declared or undeclared and regardless of the form of payment, including in connection with liquidation or conversion. The Letter Agreement further provides that the nonpayment of such dividends does not constitute a breach of or default under any transaction document.

 

In addition, the Holder waived its contractual right to require the Company to effect a reverse stock split under Section 4.10 of the Securities Purchase Agreement, including remedies for the Company’s failure to effect such a split. This waiver ceases to be effective if the Nasdaq Official Closing Price remains below the then-current Floor Price for three consecutive trading days. The Company retains the right to effect a reverse stock split at its election.

 

Between September 30, 2026 and October 14, 2026, the Holder converted an additional 19,005 shares of Series C Convertible Preferred Stock into common stock, leaving 303,235 shares of Series C Convertible Preferred Stock outstanding as of October 14, 2026. From October 15, 2026 through November 2, 2026, the Holder converted an additional 176,138 shares of Series C Convertible Preferred Stock into common stock.

 

On November 2, 2026, the Company entered into an agreement with Shakawe Capital LLC (the “Holder”) pursuant to which the Company paid aggregate consideration of $1,270,970 to repurchase and cancel all remaining 127,097 shares of Series C Convertible Preferred Stock. Upon completion of the transaction, all remaining Series C Convertible Preferred Stock was retired and cancelled, and all associated conversion rights were extinguished. As a result, no shares of Series C Convertible Preferred Stock remain outstanding, and no additional shares of common stock will be issued upon conversion of Series C Convertible Preferred Stock under the financing arrangement.

 

The repurchase and cancellation of the remaining Series C Convertible Preferred Stock eliminates the potential for further dilution to the Company’s common stockholders arising from the variable-price conversion feature of the Series C financing. The Company believes that eliminating this remaining conversion overhang provides greater flexibility in pursuing additional financing and other strategic alternatives to support its clinical development programs and ongoing operations.

 

Notice of Failure to Satisfy Nasdaq Continued Listing RuleOn November 10, 2026, the Company received a letter from the Listing Qualifications Department (the “Staff”) of Nasdaq notifying the Company that, for the 30 consecutive business days from September 29, 2026 through November 9, 2026, the closing bid price of the Company’s common stock had been below $1.00 per share, the minimum required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

 

Because the Company effected a 1-for-10 reverse stock split on June 22, 2026, within the prior one-year period, the Company is not eligible for a compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv), and the Staff has determined to delist the Company’s securities. Unless the Company requests a hearing by November 17, 2026, trading of the Company’s common stock will be suspended at the opening of business on November 19, 2026, and Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission to remove the Company’s securities from listing and registration on Nasdaq.

 

The Company intends to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”), which will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Panel’s decision. At the hearing, the Company intends to present a plan to regain compliance with the Bid Price Rule, which may include a reverse stock split. There can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will regain compliance.

 

20

 

 

Results of operations

 

Comparison of the three months ended September 30, 2026 and 2025

 

The following table summarizes our results of operations for the three months ended September 30, 2026 and 2025:

 

   Three months ended
September 30,
     
   2026   2025   Change 
Revenue  $—   $—   $— 
Operating expenses:               
Research and development   733,096   $752,931    (19,835)
General and administrative   776,476    1,126,227    (349,751)
Depreciation   1,159    1,159    — 
Total operating expenses   1,510,731    1,880,317    (369,586)
Loss from operations   (1,510,731)   (1,880,317)   369,586 
Other income (expense), net:               
Interest income   36,000    10,966    25,034 
Interest expense   —    (37,808)   37,808 
Total other income (expense), net   36,000    (26,842)   62,842 
Net loss  $(1,474,731)  $(1,907,159)  $432,428 

 

Research and development expenses

 

The following table summarizes our R&D expenses for the three months ended September 30, 2026 and 2025:

 

   Three months ended
September 30,
     
   2026   2025   Change 
             
Clinical and pre-clinical expenses  $451,811   $32,933   $418,878 
Personnel-related expenses   276,282    716,106    (439,824)
Other expenses   5,003    3,892    1,111 
Total research and development expenses  $733,096   $752,931   $(19,835)

 

Research and development expenses decreased approximately $20 thousand, or 3%, to approximately $733 thousand for the three months ended September 30, 2026, compared to approximately $753 thousand for the comparable period in 2025.

 

Personnel-related expenses decreased approximately $440 thousand, primarily reflecting a decrease of approximately $554 thousand in stock-based compensation partially offset by an increase of approximately $114 thousand in compensation expense associated with the restoration of previously reduced compensation and other compensation changes.

 

Clinical and pre-clinical expenses increased approximately $419 thousand primarily reflecting manufacturing, regulatory, and other activities supporting the Company’s 2a clinical trial of Nu-3 for iDFU. These expenditures reflect the Company’s progression from preparatory activities toward clinical execution, with the first patient dosed in September 2026. Other research and development expenses remained relatively consistent with the prior-year period.

 

General and administrative expenses

 

The following table summarizes our general and administrative expenses for the three months ended September 30, 2026 and 2025:

 

   Three months ended
September 30,
     
   2026   2025   Change 
Corporate expenses  $303,305   $144,913   $158,392 
Personnel-related expenses   255,099    749,361    (494,262)
Professional services   180,180    191,788    (11,608)
Facility costs   37,892    40,165    (2,273)
Total general and administrative expenses  $776,476   $1,126,227   $(349,751)

 

General and administrative expenses decreased approximately $350 thousand, or 31%, to approximately $776 thousand for the three months ended September 30, 2026, compared to approximately $1.1 million for the comparable period in 2025.

 

The decrease was primarily attributable to a reduction of approximately $494 thousand personnel-related expenses, partially offset by an increase of approximately $158 thousand increase in corporate expenses. The increase in corporate expenses primarily reflected higher directors’ and officers’ insurance premiums, investor relations activities, and other public company operating costs.

 

21

 

 

Personnel-related expenses decreased approximately $494 thousand, primarily reflecting a decrease of approximately $581 thousand in stock-based compensation, partially offset by an increase of approximately $87 thousand in compensation expense associated with executive compensation allocations and the restoration of previously reduced executive compensation. Professional services decreased approximately $12 thousand, while facility costs remained substantially consistent with the prior-year period.

 

Other income (expense), net

 

Other income, net was approximately $36 thousand for the three months ended September 30, 2026, compared to other expense, net of approximately $27 thousand for the comparable period in 2025, representing a favorable change of approximately $63 thousand.

 

The improvement primarily reflected an increase of approximately $25 thousand in interest income, associated with higher average cash balances following completion of the Company’s Series C financing, and a decrease of approximately $38 thousand in interest expense. The decrease in interest expense reflected the absence of interest expense on the Company’s outstanding convertible promissory notes following their automatic conversion into common stock in connection with the Company’s April 2026 Nasdaq listing. As a result, the Company generated net other income during the 2026 period compared with net other expense during the comparable prior-year period.

 

Comparison of the nine months ended September 30, 2026 and 2025

 

The following table summarizes our results of operations for the nine months ended September 30, 2026 and 2025:

 

   Nine months ended
September 30,
     
   2026   2025   Change 
Revenue  $—   $—   $— 
Operating expenses:               
Research and development   1,418,263   $1,069,536    348,727 
General and administrative   4,765,403    1,987,298    2,778,105 
Depreciation   3,476    3,476    — 
Total operating expenses   6,187,142    3,060,310    3,126,832 
Loss from operations   (6,187,142)   (3,060,310)   (3,126,832)
Other income (expense), net:               
Interest income   65,364    20,664    44,700 
Interest expense   (48,852)   (63,073)   14,221 
Other income   600    —    600 
Total other income (expense), net   17,112    (42,409)   59,521 
Net loss  $(6,170,030)  $(3,102,719)  $(3,067,311)

 

Research and development expenses

 

The following table summarizes our R&D expenses for the nine months ended September 30, 2026 and 2025:

 

   Nine months ended
September 30,
     
   2026   2025   Change 
Personnel-related expenses  $704,881   $996,339   $(291,458)
Clinical and pre-clinical expenses   698,420    62,044    636,376 
Other expenses   14,962    11,153    3,809 
Total research and development expenses  $1,418,263   $1,069,536   $348,727 

 

Research and development expenses increased approximately $349 thousand, or 33%, to approximately $1.4 million for the nine months ended September 30, 2026, compared to approximately $1.1 million for the comparable period in 2025.

 

22

 

 

Personnel-related expenses decreased approximately $291 thousand, primarily reflecting a decrease of approximately $568 thousand in stock-based compensation, partially offset by an increase of approximately $277 thousand in compensation expense associated with expanded research and development activities, changes in executive compensation allocation, and the restoration of previously reduced executive compensation.

 

Clinical and pre-clinical expenses increased approximately $636 thousand, primarily reflecting manufacturing, regulatory, and other clinical development activities supporting the Company’s Phase 2a clinical trial of Nu-3 for iDFU. These expenditures reflect the Company’s efforts to advance the trial, which commenced patient dosing in September 2026. Other research and development expenses increased by approximately $4 thousand and remained relatively consistent with the prior-year period.

 

General and administrative expenses

 

The following table summarizes our general and administrative expenses for the nine months ended September 30, 2026 and 2025:

 

   Nine months ended
September 30,
     
   2026   2025   Change 
Professional services  $3,306,376   $661,916   $2,644,460 
Personnel-related expenses   646,004    938,410    (292,406)
Corporate expenses   698,514    271,706    426,808 
Facility costs   114,509    115,266    (757)
Total general and administrative expenses  $4,765,403   $1,987,298   $2,778,105 

 

General and administrative expenses increased approximately $2.8 million, or 140%, to approximately $4.8 million for the nine months ended September 30, 2026, compared to approximately $2.0 million for the comparable period in 2025.

 

The increase was primarily attributable to approximately $2.6 million increase in professional service expenses, which included approximately $2.4 million of noncash expense related to common stock issued for placement agent advisory services and legal fees. The remaining increase in professional service expenses reflected higher legal, regulatory, and other costs associated with the Company’s Nasdaq listing and ongoing obligations as a publicly traded company.

 

Corporate expenses increased by approximately $427 thousand, primarily reflecting higher directors’ and officers’ insurance, investor relations activities, and other corporate costs associated with operating as a publicly traded company. Personnel-related expenses decreased approximately $292 thousand, primarily reflecting lower stock-based compensation, partially offset by an increase of approximately $270 thousand in compensation, including changes in executive compensation allocation and the restoration of previously reduced executive compensation. Facility costs remained relatively consistent with the prior-year period.

 

Other income (expense), net

 

Other income, net was approximately $17 thousand for the nine months ended September 30, 2026, compared to other expense, net of approximately $42 thousand for the comparable period in 2025, representing a favorable change of approximately $59 thousand.

 

Interest income increased approximately $45 thousand, primarily reflecting higher average cash balances following completion of the Company’s Series C financing. Interest expense decreased approximately $14 thousand, primarily reflecting the automatic conversion of the Company’s outstanding convertible promissory notes into common stock with the Company’s April 2026 Nasdaq listing.

 

As a result, the Company generated net other income for the nine months ended September 30, 2026, compared with net other expense during the comparable prior-year period.

 

23

 

 

Liquidity and Capital Resources

 

Since inception, the Company has financed its operations primarily through the issuance of equity securities and convertible debt. The Company has incurred recurring operating losses and negative cash flows from operations as it has advanced the development of its product candidates. At September 30, 2026, the Company had approximately $2.8 million in cash and cash equivalents, $0.5 million in certificates of deposit, and working capital of approximately $2.8 million, compared to approximately $236 thousand in cash and cash equivalents and a working capital deficit of approximately $2.1 million at December 31, 2025.

 

The significant improvement in the Company’s liquidity and financial position during the nine months ended September 30, 2026 was primarily attributable to the completion of its Series C Convertible Preferred Stock financing, which generated net proceeds of approximately $6.8 million. In addition, the automatic conversion of the Company’s outstanding Series A and Series B Convertible Preferred Stock and convertible promissory notes into common stock in connection with the Nasdaq listing significantly reduced current liabilities and simplified the Company’s capital structure.

 

Subsequent to September 30, 2026, the Company entered into and completed a Share Redemption Agreement with Shakawe Capital LLC to redeem all 127,097 remaining outstanding shares of Series C Convertible Preferred Stock for an aggregate cash payment of $1,270,970. Upon completion of the redemption, all remaining Series C Convertible Preferred Stock was cancelled and returned to treasury, and the Holder relinquished its rights associated with those shares, including conversion, dividend, liquidation preference and anti-dilution rights. The Holder also informed the Company that it had sold all shares of common stock previously issued to it upon conversion of Series C Preferred Stock through November 2, 2026.

 

The redemption eliminates the potential for further issuances of common stock resulting from conversions under the Series C financing and removes the remaining variable-price conversion overhang associated with that transaction. Management believes that eliminating this potential source of future dilution provides the Company with greater flexibility in pursuing additional financing and other strategic alternatives to support its clinical development programs and ongoing operations.

 

Based on its current operating plans and estimates, management expects that the Company’s existing cash, cash equivalents, certificates of deposit, and anticipated interest income will be sufficient to fund operations through January 2027. Management cannot assure that the Phase 2a clinical trial will be completed by then, and therefore the company is seeking to obtain additional capital to complete its planned clinical development activities and operations. The actual period for which existing resources will be sufficient will depend on the timing and amount of clinical development expenditures, other operating expenses, and additional cash requirements.

 

Management is evaluating potential sources of additional financing, including equity financings, strategic collaborations, licensing arrangements, and other sources of capital. However, there can be no assurance that the Company will be able to obtain additional financing when needed, on acceptable terms, or at all. If the Company is unable to secure sufficient additional capital, it may be required to pause its clinical development activities, curtail operations, or consider other strategic alternatives. These circumstances could materially adversely affect the Company’s business, financial condition, and ability to continue its planned operations.

 

Cash flows

 

For the nine months ended September 30, 2026 and 2025

 

The following table summarizes our cash flows for the nine months ended September 30, 2026 and 2025:

 

   For the Nine Months Ended
September 30,
 
   2026   2025 
Net cash used in operating activities  $(3,714,859)  $(1,522,688)
Net cash used in investing activities   (500,000)   — 
Net cash provided by financing activities   6,802,095    1,500,000 
Net increase (decrease) in cash and cash equivalents  $2,587,236   $(22,688)

 

Operating Activities

 

Net cash used in operating activities increased by approximately $2.2 million, from approximately $1.5 million for the nine months ended September 30, 2025 to approximately $3.7 million for the comparable period in 2026. The increase reflects the Company’s operating expenditures as it continued to advance its clinical development programs and incur costs associated with its Nasdaq listing and ongoing public-company reporting and compliance obligations.

 

In reconciling net loss to net cash used in operating activities, the Company recognized significant noncash expenses, including approximately $2.4 million related to the issuance of common stock for placement-agent advisory services, as well as stock-based compensation and other noncash items. These noncash expenses affected reported net loss but did not require corresponding cash payments during the period.

 

Investing Activities

 

Net cash used in investing activities was approximately $0.5 million for the nine months ended September 30, 2026, compared to no investing activities during the comparable prior-year period in 2025. Investing activities primarily reflected purchases of certificates of deposit, partially offset by maturities of previously purchased certificates of deposit. These transactions represented the Company’s management of available cash resources to earn interest while maintaining funds to support its operating activities.

 

24

 

 

Financing Activities

 

Net cash provided by financing activities was approximately $6.8 million for the nine months ended September 30, 2026, compared to approximately $1.5 million for the comparable period in 2025. Financing activities during the 2026 period consisted primarily of the net proceeds of approximately $6.8 million from the issuance of the Company’s Series C Convertible Preferred Stock. Financing activities during the comparable 2025 period consisted of proceeds received from convertible promissory notes used to fund the Company’s operations.

 

Material Cash Requirements

 

The Company’s material cash requirements consist primarily of expenditures to support its clinical development programs, personnel costs, professional services, facility lease obligation, and general corporate operating expenses.

 

Operating Lease

 

The Company leases office space in University Park, Florida, under a non-cancelable operating lease that expires on April 30, 2027. The Company expects to satisfy its lease obligations through cash generated from its existing liquidity resources. Additional information regarding the Company’s lease commitments is included in Note 5 to the condensed financial statements included elsewhere in this Quarterly Report.

 

Research and Development Commitments

 

The Company expects to continue to incur significant expenditures related to the development of Nu-3 (Bisphosphocin® gel formulation), including manufacturing, regulatory, clinical trial, and other development activities associated with its ongoing Phase 2a clinical trial. The Company has entered into agreements with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), laboratories, and other third-party service providers to support these activities. The timing and amount of future payments under these arrangements will depend on the progress of clinical development and other research activities. Additional information regarding the Company’s research and development commitments is included in Note 5 to the condensed financial statements included elsewhere in this Quarterly Report.

 

Public Company Costs

 

As a Nasdaq-listed public company, the Company expects to continue to incur increased costs associated with SEC reporting, Nasdaq listing fees, legal and accounting services, directors’ and officers’ insurance, investor relations, and other corporate governance and compliance requirements. Management expects these expenditures to remain higher than historical levels as the Company continues to operate as a public reporting company.

 

The Company expects to fund these cash requirements through its existing cash, cash equivalents, short-term investments and as necessary, future financing activities.

 

Critical Accounting Policies and Estimates

 

The preparation of our condensed financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

 

There have been no material changes to the Company’s critical accounting policies and estimates from those described in the Company’s Registration Statement on Form S-1 (File No. 333-292664), as amended, during the nine months ended September 30, 2026.

 

25

 

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

We do not hold any derivative instruments and do not engage in any hedging activities.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

The Company maintains disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (“SEC”). These disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), as appropriate, to allow timely decisions regarding required disclosure.

 

As of September 30, 2026, management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures, as required by Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, management concluded that the Company’s disclosure controls and procedures were not effective as of September 30, 2026 due to the material weaknesses in internal control over financial reporting described below.

 

The material weaknesses identified by management include the following:

 

  ● Limited documentation of the Company’s system of internal control over financial reporting, including formal control policies and procedures.

 

  ● Limited segregation of duties in the handling of cash receipts, cash disbursements and other accounting functions due primarily to the Company’s limited number of employees.

 

  ● Insufficient management review controls over significant accounting areas, including investments, earnings per share, stock-based compensation, income taxes and right-of-use lease accounting.

 

  ● Information technology general controls that were not designed and operating effectively to appropriately restrict access to applications and data, maintain appropriate segregation of duties, and monitor changes to financial information.

 

The material weaknesses described above are the same material weaknesses previously disclosed in the Company’s Registration Statement on Form S-1 and Quarterly Reports on Form 10-Q for the quarters ended March 31, and June 30, 2026. The Company continues to evaluate and implement remediation measures intended to address these material weaknesses, including enhancing documentation and review procedures, strengthening access and monitoring controls, and utilizing external consultants and other resources where appropriate. Because of the Company’s limited personnel and financial resources, remediation efforts are expected to be implemented over time. While management is committed to strengthening the Company’s internal control environment, there can be no assurance regarding the timing of remediation or whether the implemented measures will fully remediate the identified material weaknesses.

 

Notwithstanding the material weaknesses described above, our management, including the Chief Executive Officer and Chief Financial Officer, has concluded that unaudited condensed financial statements, and other financial information included in this quarterly report, fairly present in all material respects our financial condition, results of operations, and cash flows as of and for the periods presented in this quarterly report.

 

Changes in Internal Controls

 

There were no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act, as of 1934, as amended) during the fiscal quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

26

 

 

PART II-OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

There are no actions, suits, proceedings, inquiries or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company, threatened against or affecting our company, our common stock, in which an adverse decision could have a material adverse effect.

 

Item 1A. Risk Factors.

 

Not required because we are a smaller reporting company.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

(a) Unregistered Sales of Equity Securities

 

On January 31, 2026, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company agreed to sell an aggregate of 937,500 shares of Series C Convertible Preferred Stock in a private placement exempt from registration pursuant to Rule 506(b) of Regulation D under the Securities Act. The Series C Convertible Preferred Stock has an aggregate stated value of $9.375 million, and the investor purchased the shares for an aggregate purchase price of $7.5 million, representing a 20% original issue discount.

 

The financing closed on April 21, 2026, and generated net proceeds to the Company of approximately $6.8 million after payment of placement agent fees and other offering-related expenses.

 

On April 21, 2026, the Company issued 658 shares of Common Stock to its SEC counsel in consideration for legal services provided in connection with the Company’s securities filings and Nasdaq listing. The shares were valued at $75,000 and the amount was recorded as professional fees. The issuance was exempt from registration pursuant to Section 4(a)(2) of the Securities Act.

 

On April 23, 2026, upon the Company’s listing on the Nasdaq Capital Market, the Company issued 27,273 shares of common stock to the Placement Agent representing the Advisory Shares valued at $2,359,080. The issuance was exempt from registration pursuant to Section 4(a)(2) of the Securities Act.

 

(b) Use of Proceeds

 

None

 

(c) Issuer Purchases of Equity Securities

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures (Removed and Reserved)

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

27

 

 

Item 6. Exhibits

 

The exhibit index set forth below is incorporated by reference in response to this Item 6.

 

Exhibit
Index
  Description
3.1   Fourth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s S-1/A, Registration No. 333-292664, filed with the SEC on February 5, 2026).
3.2   Articles of Conversion (incorporated by reference to Exhibit 3.2 to the Registrant’s S-1/A, Registration No. 333-292664, filed with the SEC on February 5, 2026).
3.3   Certificate of Amendment dated September 29, 2025 (incorporated by reference to Exhibit 3.3 to the Registrant’s S-1/A, Registration No. 333-292664, filed with the SEC on February 5, 2026).
3.4   Form of Amendment to Fourth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.4 to the Registrant’s S-1/A, Registration No. 333-292664, filed with the SEC on February 5, 2026).
3.5   Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s S-1, Registration No. 333-292664, filed with the SEC on January 9, 2026).
10.1   2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s S-1, Registration No. 333-292664, filed with the SEC on January 9, 2026).
10.2   Form of Stock Option Agreement (Employee) under the 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s S-1, Registration No. 333-292664, filed with the SEC on January 9, 2026).
10.3   Form of Stock Option Agreement (Non-Employee) under the 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s S-1, Registration No. 333-292664, filed with the SEC on January 9, 2026).
10.4   Employment Agreement, dated September 15, 2025, by and between the Company and Thomas Balzer (incorporated by reference to Exhibit 10.4 to the Registrant’s S-1, Registration No. 333-292664, filed with the SEC on January 9, 2026).
10.5   Employment Agreement, dated September 15, 2025, by and between the Company and Kelvin Cooper (incorporated by reference to Exhibit 10.5 to the Registrant’s S-1, Registration No. 333-292664, filed with the SEC on January 9, 2026).
10.6   Employment Agreement, dated September 15, 2025, by and between the Company and Peter Ceccacci (incorporated by reference to Exhibit 10.6 to the Registrant’s S-1, Registration No. 333-292664, filed with the SEC on January 9, 2026).
10.7   Board of Directors Agreement, dated April 24, 2026, between the Company and Joseph Tucker (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on April 28, 2026).
10.8   Warrant Agreement, dated April 24, 2026, between the Company and Joseph Tucker (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on April 28, 2026).
10.9   Board of Directors Agreement, dated July 1, 2021, between the Company and Douglas Joseph Manion (incorporated by reference to Exhibit 10.8 to the Registrant’s S-1/A, Registration No. 333-292664, filed with the SEC on February 5, 2026).
10.10   Board of Directors Agreement, dated July 12, 2017, between the Company and Leonard J. DeRoma (incorporated by reference to Exhibit 10.9 to the Registrant’s S-1/A, Registration No. 333-292664, filed with the SEC on February 5, 2026).
10.11   Registration Rights Agreement, dated January 31, 2026, between the Company and the Purchaser (incorporated by reference to Exhibit 10.10 to the Registrant’s S-1/A, Registration No. 333-292664, filed with the SEC on February 5, 2026).
10.12   Securities Purchase Agreement, dated January 31, 2026, between the Company and the Purchaser (incorporated by reference to Exhibit 10.11 to the Registrant’s S-1/A, Registration No. 333-292664, filed with the SEC on February 5, 2026).

 

28

 

 

10.13   Certificate of Designations of Preferences, Limitations, Restrictions and Relative Rights of Series C Preferred Stock of the Company (incorporated by reference to Exhibit 10.12 to the Registrant’s S-1/A, Registration No. 333-292664, filed with the SEC on February 5, 2026).
10.14   Form of Warrant Agreement between the Company and the Holder (incorporated by reference to Exhibit 10.13 to the Registrant’s S-1, Registration No. 333-292664, filed with the SEC on January 9, 2026).
10.15   Financial Advisory and Placement Agency Agreement, dated February 10, 2025, by and between the Company and RBW Capital Partners LLC (incorporated by reference to Exhibit 10.14 to the Registrant’s S-1, Registration No. 333-292664, filed with the SEC on January 9, 2026).
10.16   Amendment to Financial Advisory and Placement Agency Agreement, dated March 7, 2025, by and between Company and RBW Capital Partners LLC (incorporated by reference to Exhibit 10.15 to the Registrant’s S-1, Registration No. 333-292664, filed with the SEC on January 9, 2026).
10.17*   Amendment to the 2020 Equity Incentive Plan, approved by shareholders on September 22, 2026
31.1*   Certification of Chief Executive Officer, dated November 16, 2026 pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Chief Financial Officer, dated November 16, 2026 pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*   Certification of Chief Executive Officer, dated November 16, 2026 pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*   Certification of Chief Financial Officer, dated November 16, 2026, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

* Filed herewith.

 

29

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.  
     
  By: /s/ Kelvin Cooper
  Name: Kelvin Cooper
  Title: Chief Executive Officer
(Principal Executive Officer)  
     
  By: /s/ Peter Ceccacci
  Name: Peter Ceccacci
  Title: Chief Financial Officer
    (Principal Financial Officer)

 

Dated: November 16, 2026

 

30

Keep reading